

1 **Title Page**

2 **Article type:** Original Research Article

3 **Title:** Pruritus and its Association with Cancer and Mortality in Dermatomyositis and
4 Polymyositis: A Nationwide Cohort Study in Taiwan from 2005 to 2022

5 **Contributors:**

6 1. Der-Jr Huang¹, M.D.

7 2. Yu-Hsuan Joni Shao^{2,3,4}, PhD

8 3. Yi-Hsien Shih^{1,5,6}, M.D., PhD

9 4. Woan-Ruoh Lee¹, M.D., PhD

10 5. Ling-Ya Huang⁴

11 6. Yu-Min Kuo^{7,8}, M.D., PhD

12 7. Quoc Thao Trang Pham^{9,10}, M.D.

13 8. Hao-Jui Weng^{1,5,6,9}, M.D., PhD (Orcid: 0000-0002-7006-7599)

14 1 Department of Dermatology, Taipei Medical University-Shuang Ho Hospital, New Taipei
15 City, Taiwan

16 2 Graduate Institute of Biomedical Informatics, College of Medical Science and Technology,
17 Taipei Medical University, Taipei, Taiwan

18 3 Clinical Big Data Research Center, Taipei Medical University Hospital, Taipei, Taiwan

19 4 Health Data Analytics and Statistics Center, Office of Data Science, Taipei Medical
20 University, Taipei, Taiwan

21 5 Department of Dermatology, School of Medicine, College of Medicine, Taipei Medical
22 University, Taipei, Taiwan

23 6 Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University,
24 Taipei, Taiwan

25 7 Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine,
26 National Taiwan University, Taipei, Taiwan

27 8 Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University,
28 Taipei, Taiwan

29 9 International Ph.D. Program for Cell Therapy and Regeneration Medicine, College of
30 Medicine, Taipei Medical University, Taipei, Taiwan.

31 10 Department of Dermatology, Faculty of Medicine, University of Medicine and Pharmacy
32 at Ho Chi Minh City, Ho Chi Minh City, Vietnam.

33

34 **Corresponding author:**

35 Hao-Jui Weng, M.D., PhD, Department of Dermatology, Taipei Medical University-Shuang
36 Ho Hospital, No. 291, Zhongzheng Rd., Zhonghe District, New Taipei City, 23561, Taiwan,

37 TEL: +886931073192

38 Email: wenghaojui@tmu.edu.tw

39 **Declarations**

40 **Funding sources:** This work was supported by Taipei Medical University-Shuang Ho
41 Hospital, Ministry of Health and Welfare (112YSR-02), and National Science and
42 Technology Council (110-2314-B-038-028-MY3).

43 **Conflicts of interest/Competing interests:** None to declare.

44 **Consent to participate (including appropriate statements):** Not applicable

45 **Ethical approval:** The study was approved by the Joint Institutional Review Board of Taipei
46 Medical University (N202403054). The requirement for informed consent was waived by the
47 Institutional Review Board because the dataset was deidentified.

48 **Prior presentation:** The abstract of this study was presented at EADV Congress 2024 at
49 Amsterdam on 26 September 2024.

50 **Reprint requests:** None

51 **Data Availability Statement:** Data are available from the National Health Insurance
52 Research Database (NHIRD) published by the Taiwan National Health Insurance (NHI)
53 Bureau. Due to legal restrictions imposed by the government of Taiwan in relation to the
54 Personal Information Protection Act, data cannot be made publicly available. Requests for
55 data can be sent as a formal proposal to the NHIRD (<https://nhird.nhri.org.tw>).

56

57

58 **Acknowledgments:**

59 We acknowledge the statistical support of the Health Data Analytics and Statistics Center,
60 Office of Data Science, Taipei Medical University, Taiwan. This work was supported by
61 Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare (112YSR-02),
62 and National Science and Technology Council (110-2314-B-038-028-MY3).

63

64 **Author contributions:** DJH conceptualised the study, contributed to the study design and
65 interpretation of the results, and drafted the manuscript. YHJS contributed to the study
66 design, data extraction, and analysis, and reviewed the manuscript. WRL and YHS
67 contributed to the study design and reviewed the manuscript. LYH contributed to the study
68 design, data analysis, and interpretation of the results, and reviewed the manuscript. YMK
69 and QTTP contributed to the interpretation of the results and reviewed the manuscript. HJW
70 conceptualized the study, contributed to the study design and interpretation of the results,
71 and reviewed the manuscript. All authors had access to the final study results and accepted
72 responsibility for submitting them for publication. The corresponding author attests that all
73 listed authors meet authorship criteria and that no others meeting the criteria have been
74 omitted. HJW is the guarantor.
75

76 **Manuscript word count:** 3572 words

77 **Abstract word count:** 258 words

78 **References:** 97

79 **Figures:** 2

80 **Tables:** 3

81 **Supplementary tables:** 7

82

83 **Abbreviations:**

84 DM: dermatomyositis

85 PM: polymyositis

86 ILD: interstitial lung disease

87 NHIRD: National Health Insurance Research Database

88 International Classification of Diseases, Ninth Revision: *ICD-9*

89 International Classification of Diseases, Tenth Revision: *ICD-10*

90 HR: hazard ratio

91 CI: confidence interval

92 PG: pruritic group

93 LPG: long-term pruritic group

94 SPG: short-term pruritic group

95 NPG: nonpruritic group

96

97 **Abstract**

98 **Background:**

99 Pruritus is the most common initial symptom reported by patients with dermatomyositis and
100 polymyositis. However, there is limited data regarding the impact of pruritus on cancer and
101 mortality in patients with dermatomyositis and polymyositis.

102 **Objective:**

103 To investigate the associations of pruritus to cancer and mortality in patients with
104 dermatomyositis and polymyositis.

105 **Methods:**

106 This nationwide, population-based retrospective cohort study included adult
107 dermatomyositis and polymyositis patients from Taiwan's National Health Insurance
108 Research Database between 2005 and 2022. Sex- and age-matched pruritic patients,
109 identified by over six weeks of antipruritic medication use, and nonpruritic patients were
110 analyzed. The primary outcome was cancer occurrence or all-cause mortality.

111 **Results:**

112 Among 919 matched pairs of pruritic and non-pruritic patients, cancer was observed in
113 19.96% in the long-term pruritic group, 14.63% in the short-term pruritic group, and 10.34%
114 in the nonpruritic group ($p < 0.0001$). All-cause mortality was documented at 30.37% in the
115 long-term pruritic group, 29.69% in the short-term pruritic group, and 37.76% in the
116 nonpruritic group ($p < 0.0001$). Pruritus was associated with an increased risk of cancer
117 (hazard ratio 1.492, 95% confidence interval 1.093-2.036), and a lower risk of all-cause
118 mortality (hazard ratio 0.489, 95% confidence interval 0.419-0.571).

119 **Conclusion:**

120 This population-based study revealed pruritus appeared to be associated with increased
121 cancer risk and decreased all-cause mortality. Thus, pruritus may serve as a pragmatic
122 factor for risk stratification and tailored treatment strategies in dermatomyositis and
123 polymyositis. Comprehensive cancer screening is recommended for patients with
124 dermatomyositis or polymyositis, particularly those presenting with pruritus, whereas
125 patients without pruritus may require vigilant management for potentially life-threatening
126 complications and comorbidities.

127

128 **Key points**

- 129 1. Previous single-institutional studies and studies with small cohorts reported conflicting
130 data regarding the impact of pruritus on cancer and mortality in patients with
131 dermatomyositis and polymyositis
- 132 2. Pruritus in dermatomyositis and polymyositis appeared to be associated with increased
133 cancer risk and decreased all-cause mortality.
- 134 3. Our findings suggest that pruritus may serve as a pragmatic factor for risk stratification
135 and tailored treatment strategies in dermatomyositis and polymyositis.

136

137 **1 Introduction**

138 Dermatomyositis (DM) and polymyositis (PM) are rare but debilitating autoimmune diseases.
139 In the United States, the annual incidence of DM is 9.63 cases per million people.[1] In
140 Taiwan, DM and PM together occur at a frequency of 11.5 cases per million people.[2] Both
141 conditions are characterized by progressive symmetrical proximal muscle weakness. DM
142 also presents distinct skin manifestations, such as pruritus, heliotrope rash, and Gottron's
143 papules. Additionally, patients with DM and PM have increased risks of cancer, interstitial
144 lung disease, stroke,[3–6] and ischemic heart disease, [5–7] and possess one of the
145 poorest prognoses among connective tissue diseases.

146

147 Pruritus is the most common initial symptom reported by patients with DM, and associated
148 with increased cutaneous severity. Up to 63% to 90% of patients with DM experience
149 pruritus during the disease course.[1,8,9] Furthermore, pruritus in DM is associated with
150 poor mental health and has a more significant impact on quality of life than other pruritic
151 dermatosis, such as psoriasis and atopic dermatitis. [9–12]

152

153 Pruritus has been identified as a notable prognostic factor in several diseases. In conditions
154 such as Hodgkin's lymphoma[13,14] and hemodialysis,[15] pruritus is associated with
155 poorer survival. Conversely, in polycythemia vera, pruritus is associated with a lower risk of
156 arterial thrombosis and improved survival.[16] Furthermore, pruritus might serve as a
157 marker of occult cancer, regardless of the type of underlying disease.[17] Regarding DM
158 and PM, previous studies have shown that pruritus was correlated with an elevated risk of
159 cancers,[18–20] while one study presented contradictory evidence.[21] This discrepancy
160 highlights the need for large-scale studies to investigate the association between pruritus
161 and its complications in patients with DM and PM.

162

163 In this study, we investigated the potential association between pruritus and cancer risk in
164 patients with DM and PM, by using Taiwan's national database and registry. We aimed to
165 investigate the impact of pruritus on the risk of cancer in DM or PM, and the association
166 between pruritus and overall survival in these patients. Through our investigation, we
167 elucidated the clinical importance of pruritus, which may help stratify these patients into
168 subgroups and guide management strategies in DM and PM.

169

170 **2 Methods**

171 **2.1 Data sources**

172 All participant data were obtained from the Registry of Catastrophic Illness Database in
173 Taiwan, a subset of the National Health Insurance Research Database (NHIRD). This
174 database was established for public research purposes as part of Taiwan's National Health
175 Insurance Program, which was initiated in 1995 and covered more than 99% of Taiwan's
176 23 million residents. The case definitions of DM and PM were strictly limited to the ones
177 who underwent comprehensive clinical and laboratory assessments that met the diagnostic
178 criteria by Bohan and Peter.[22,23] Only patients with a diagnosis of probable or definite
179 DM and PM were given the catastrophic illness certificate. The accuracy and validity
180 regarding dermatomyositis and polymyositis in the Registry of Catastrophic Illness
181 Database have been well-established in prior studies.[2,24]

182

183 **2.2 Study design and participants**

184 Data on patients with DM or PM diagnosed between January 1, 2005, and December 31,
185 2022, were extracted from the Registry of Catastrophic Illness Database in Taiwan by using

186 the International Classification of Diseases, Ninth Revision (*ICD-9*) and International
187 Classification of Diseases, Tenth Revision (*ICD-10*) codes (supplementary table S1).
188 To minimize bias, patients with DM or PM with concurrent conditions potentially associated
189 with pruritus were excluded, such as atopic dermatitis, urticaria, psoriasis, mycosis
190 fungoides, and Sezary syndrome (as defined using *ICD-9* and *ICD-10* codes;
191 supplementary table S1). Additionally, patients undergoing dialysis (as identified using
192 expenditure codes; supplementary table S1) were excluded. Given the high prevalence of
193 atopic dermatitis and urticaria, only patients with two consecutive diagnoses of these
194 conditions were excluded.

195

196 **2.3 Definition of pruritus**

197 The index date for a patient with DM or PM was defined as the date of the first medical
198 record related to the diagnosis. The cases with chronic pruritus were defined based on the
199 methodology previously outlined by Ting et al.[25] Patients with DM or PM who were
200 prescribed antipruritic agents for 42 consecutive days or more after the index date were
201 included in the pruritic group (PG) (as defined using Anatomical Therapeutic Chemical
202 codes, including systemic or topical antihistamines; menthol lotion; and combination
203 ointments containing chlorpheniramine maleate, lidocaine hydrochloride, hexachlorophene,
204 methyl salicylate, menthol, and camphor; supplementary table S2), and further divided into
205 long-term pruritic group (LPG) for those treated for 84 days or more and short-term pruritic
206 group (SPG) for those treated for 42 to 83 days. Prescriptions separated by an interval
207 shorter than 30 days were also considered consecutive. Patients without prescriptions for
208 antipruritic agents, or those prescribed such agents for less than 42 consecutive days, were
209 classified into the nonpruritic group (NPG). To exclude other indications for prescribing
210 antihistamines, prescriptions given under the diagnosis of allergic rhinitis (defined by *ICD-9*

211 and *ICD-10* codes; supplementary table S1) were removed from the prescription records.

212

213 **2.4 Outcome measurement**

214 The primary outcomes of interest were cancer and ILD development, as well as mortality.

215 Cancer development was defined as receiving a diagnosis corresponding to the

216 International Classification of Diseases for Oncology, Third Edition codes C00–C97 in the

217 Taiwan Cancer Registry between 2005 and 2022. The diagnoses related to nonmelanoma

218 skin cancer and metastasis were excluded (defined by *ICD-9* and *ICD-10* codes;

219 supplementary table S3). Cancer cases were further categorized into two groups, based on

220 registration date within 5 years prior to, and 10 years after the index date. The mortality and

221 cause of death were determined from 2005 to 2022, using the National Death Registry in

222 Taiwan.

223 To minimize the influence of potential confounding factors, additional factors including age

224 at index date, sex, and comorbidities known to be associated with both outcome risk and

225 pruritus were evaluated. Comorbidities, including diabetes mellitus, hypertension, and other

226 medical conditions were defined by *ICD-9* and *ICD-10* codes documented at least twice in

227 outpatient department visits or once during inpatient admissions before the index date

228 (supplementary table S1).

229

230 **2.5 Statistical analysis**

231 The distributions of the demographic characteristics, and comorbidities of the patients with

232 DM and PM, were presented as frequencies (percentages) for categorical variables,

233 medians (with interquartile ranges) for continuous variables, and means \pm standard

234 deviations for approximately normally distributed continuous variables. Differences in

235 distribution proportions of categorical variables were assessed using the Cochran–Mantel–

236 Haenszel test, whereas the mean differences in continuous variables between the two
237 groups were evaluated using the generalized estimating equation. Survival analysis was
238 performed by the Kaplan-Meier method. Hazard ratios (HRs) and 95% confidence intervals
239 (CIs) were estimated using multivariable Cox proportional-hazard models to investigate the
240 association between pruritus and the risk of newly diagnosed cancer development and all-
241 cause mortality. The individual risk of each confounding factor was assessed using simple
242 Cox proportional-hazard models, and confounders exhibiting significant outcome risks were
243 subsequently included in multivariable Cox proportional-hazard models for adjustment. All
244 statistical analyses were conducted using SAS software (version 9.4, SAS Institute, Cary,
245 NC, USA), with a two-sided p-value of <0.05 considered significant.

246

247 **2.6 Sensitivity analyses**

248 To assess the impact of the pruritus definition cutoff point on the outcome measurement,
249 sensitivity analyses were conducted.

250

251 **3 Results**

252 **Baseline characteristics of the DM/PM cohort**

253 From 2005 to 2022, 2,723 patients listed on the NHIRD were diagnosed with DM or PM
254 (Figure 1). Among these patients, 122 were excluded for age younger than 18 years, and
255 469 were excluded for concomitant pruritus-associated diseases (212 with atopic dermatitis,
256 95 with urticaria, 122 with psoriasis, 4 with mycosis fungoides, and 90 undergoing dialysis).
257 A total of 2,132 patients with DM or PM remained. They were categorized into the PG
258 (1,180 patients) and the NPG (952 patients) based on their antipruritic medication
259 prescriptions. After matching by date of birth (± 2 years) and sex at a ratio of 1:1, 919
260 patients of DM/PM with pruritus (PG) and 919 without (NPG) were included in the analysis.

261 The demographic data of the overall cohort (patients with DM and PM) were examined.
262 The average follow-up time was 6.7 years. Our cohort exhibited a female predominance,
263 with a male-to-female ratio of approximately 1:2 (Table 1). The mean age at the index date
264 was 52.0 years in the LPG, 51.6 years in the SPG, and 51.8 years in the NPG. No
265 significant baseline difference in comorbidities was observed.

266

267 **3.1 Association between pruritus and cancer**

268 To investigate the association between pruritus and cancers in patients with DM or PM, we
269 analyzed the prevalence of cancers, before and after the diagnosis of DM and PM, in the
270 matched groups. For the overall cohort, a higher percentage of patients in the LPG and
271 SPG developed cancer than in the NPG, over the 5 years prior to, and 10 years after the
272 index date (Table 2; 19.96% for LPG, 14.63% for SPG, and 10.34% for NPG; $p < 0.0001$).
273 We next investigated the association between specific cancers and pruritus among patients
274 with DM or PM. In our cohort, nasopharyngeal cancer, breast cancer, lung cancer, and
275 colorectal cancer were the most prevalent cancer types, representing 20.2%, 15.4% 15.4%,
276 and 12.5% of cancers, respectively. Increased prevalence was noted in the pruritic group
277 for nasopharyngeal cancer (4.72% vs. 1.05%, $p < 0.0001$). A similar trend was observed in
278 breast cancer (2.83% vs. 1.57%, $p = 0.05$).

279

280 **3.2 Association between pruritus and mortality**

281 In contrast to the association observed between cancer and pruritus, we identified a
282 significantly lower all-cause mortality rate in the LPG and the SPG, than in the NPG (Table
283 2). Among the overall cohort during the 18-year follow-up period, the all-cause mortality rate
284 was 30.37% in the LPG, 29.69% in the SPG, and 37.76% in the NPG ($p < 0.0001$).

285 Further analysis of the causes of death in the study population, revealed an elevated risk of

286 cancer-related mortality in the LPG and SPG, among patients with DM and PM. For the
287 overall cohort, our findings revealed 11.50% of patients in the LPG, and 6.77% of patients
288 in the SPG, died from various types of cancers, whereas only 5.88% died in the NPG
289 ($p=0.04$).

290 Kaplan-Meier survival curves for the overall cohort (Figure 2) showed a significant
291 difference between the PG and the NPG ($p<0.0001$). A higher proportion of deaths in the
292 NPG occurred within the first year after DM or PM diagnosis, compared to deaths in the PG.
293 Among the overall cohort, the 1-year survival rate was 95% in the PG, compared to only
294 77% in the NPG. This disparity was particularly pronounced among patients with DM,
295 where the 1-year survival rate was 93% in the PG, compared to 68% in the NPG.

296

297 **3.3 Hazard ratio analysis of pruritus in DM and PM**

298 To investigate the variables for patients' survival, simple Cox proportional-hazard models
299 were utilized. The results supported our previous data, that the presence of pruritus during
300 the disease course, was associated with a higher risk of newly diagnosed cancers for the
301 overall cohort (supplementary table S5; HR 1.561, 95% CI 1.154-2.111). Subgroup analysis
302 revealed that long-term pruritus was significantly associated with cancer (HR 1.971, 95% CI
303 1.416-2.744), while short-term pruritus showed no significant association with cancer.

304 Furthermore, older age of onset, including ages between 40 and 65 years, >65 years, male
305 sex, diabetes mellitus, hypertension, and vasculitis, were significantly associated with newly
306 diagnosed cancers.

307 The presence of pruritus, in contrast, was negatively associated with the mortality for
308 the overall cohort (supplementary table S6; HR 0.564, 95% CI 0.490-0.650). Subgroup
309 analysis identified both long-term and short-term pruritus were significantly associated with
310 mortality (HR 0.591, 95% CI 0.494-0.707; HR 0.539, 95% CI 0.450-0.646, respectively).

311 However, older age of onset, including an age between 40 and 65 years, >65 years, male
312 sex, diabetes mellitus, hypertension, ILD, and cancer, were positively associated with
313 mortality.

314 In the multivariable analysis for newly diagnosed cancer, adjustment was performed for
315 significant confounding factors, including sex, age, diabetes, hypertension, vasculitis, and
316 arthritis. Additionally, ILD and cancer were considered in the analysis of mortality risk. The
317 multivariate analysis (Table 3) indicated that pruritus was associated with an increased risk
318 of developing cancer (HR 1.492, 95% CI 1.093-2.036), with a more pronounced effect for
319 long-term pruritus (HR 1.849, 95% CI 1.314-2.602). Conversely, pruritus was associated
320 with a lower risk of mortality (HR 0.489, 95% CI 0.419-0.571).

321 The sensitivity analyses confirmed the robustness of the results (supplementary table
322 S7). We consistently observed associations between pruritus and cancer, as well as
323 pruritus and mortality, across various pruritus duration thresholds.

324

325 **4 Discussion**

326 This study demonstrated the association between pruritus in patients with DM and PM, and
327 their comorbidities and prognostic outcomes at a national level. Patients with DM and PM
328 experiencing pruritus were found to have a higher risk of developing cancers, but a lower
329 risk of all-cause mortality, compared to nonpruritic patients. This finding was complemented
330 by similar results in the sensitivity analyses. More than half of our cohort experienced
331 chronic pruritus, highlighting the need for ongoing and comprehensive screening for
332 cancers in this high-risk patient population.

333

334 Pruritus has long been documented in autoimmune connective tissue diseases.[26]

335 Approximately 57% of patients with autoimmune connective tissue diseases, irrespective of

336 their specific diagnoses, report pruritus upon their initial presentation.[27] The prevalence of
337 pruritus varies across different diseases, ranging from 42% to 62% in systemic
338 sclerosis,[27–30] 38% to 53% in Sjögren syndrome,[31,32] and 63% to 90% in DM.[1,8,9]
339 Pruritus in lupus erythematosus (LE) is generally considered less severe than that in
340 DM.[12,27] Studies have indicated that the median pruritus visual analogue scale score in
341 LE is significantly lower than that observed in DM (3.8 vs. 2.0).[12] Moreover, the majority of
342 patients with LE experience only mild (45% to 62%) or moderate (54%) pruritus,[27,33]
343 which contrasts with reports from patients with DM. For the underlying cause, small fiber
344 neuropathies, paraneoplastic symptoms, and involvement of IL-31 are believed to
345 contribute to DM-associated itch. Kim et al. revealed upregulation of IL-31 and its receptor
346 alpha gene in the lesional skin of patients with DM,[9] with IL-31 exhibiting a significant
347 positive correlation with the severity of itch.

348

349 Assessing antihistamine usage may serve as a surrogate indicator for a patient's pruritus in
350 our study as previously reported.[25] In clinical practice, sedating antihistamines are
351 commonly prescribed as first-line treatment for pruritus.[34] They alleviate pruritus by
352 blocking H1 receptors on C-afferent fiber terminals,[35] preventing mast cell
353 degranulation,[36,37] and providing a soporific effect. While not all pruritic diseases could
354 be effectively controlled by antihistamines, most patients with chronic pruritus, regardless of
355 its cause, will receive H1 antihistamines at some point to alleviate the itch.[38,39]

356 Antihistamines are favored for their proven efficacy in other pruritic dermatosis, such as
357 chronic idiopathic urticaria,[40–43] atopic dermatitis, and psoriasis,[44] as well as their
358 affordability, accessibility, and minimal side effects. The cut-off point for antihistamine usage
359 was set at 6 weeks in our study, as chronic pruritus is defined by the International Forum for
360 the Study of Itch as itching that persists for over 6 weeks.[45] Short-term antihistamine uses

361 for other conditions such as allergic reactions were excluded.

362

363 Using multivariable Cox proportional-hazard models, we found that DM and PM patients
364 experiencing pruritus exhibited a significantly higher risk of newly diagnosed cancer (Table
365 3; adjusted HR 1.492, 95% CI 1.093-2.036). Previous studies show that DM patients with
366 pruritus may be predisposed to internal malignancies,[18–20] with one contradictory study
367 of 63 patients in Germany.[21] However, due to limited sample sizes in earlier studies, their
368 findings regarding the association between pruritus and cancer, appeared inconclusive or
369 underpowered. Our findings, in contrast, provided robust evidence supporting the notion
370 that DM and PM patients with pruritus exhibit an elevated risk of cancer.

371

372 Many autoimmune diseases have been associated with a higher risk of developing cancers.
373 For example, Sjögren's syndrome is associated with an increased risk of non-Hodgkin
374 lymphoma,[46,47] and systemic lupus erythematosus is associated with non-Hodgkin
375 lymphoma and lung cancer.[48–50] Additionally, systemic sclerosis is linked to an elevated
376 risk of lung cancer.[51–53] DM is associated with a higher cancer risk compared with other
377 autoimmune diseases. Approximately 2.2% to 5% of patients with Sjögren's syndrome
378 develop cancers,[47,54,55] compared to a higher prevalence of 9.4% to 32.3% among
379 patients with DM.[2,56–60] Some scholars have postulated that in DM, cancer itself
380 triggered autoimmunity rather than as the result of disordered immune function or
381 immunosuppressive drugs, which have been implicated in the pathogenesis of cancer in
382 other autoimmune diseases.[61–64] In our analysis, the majority of the patients with DM or
383 PM developed cancers within a year before or after the diagnosis of DM or PM. This is
384 consistent with the findings of prior research. Furthermore, studies have indicated that the
385 increased risk of cancers may persist beyond the initial 5-year period. Thus, sustained and

386 comprehensive cancer screening is necessary for patients with DM or PM, particularly
387 those deemed to be at high risk following their diagnosis.

388

389 The multivariable Cox proportional-hazard models also identified pruritus as a protective
390 factor against all-cause mortality in patients with DM and PM (Table 3; adjusted HR 0.489,
391 95% CI 0.419-0.571). Prior studies showed cancer, ILD, infection, and cardiac involvement
392 as predominant causes of death in DM and PM patients.[65–73] The most common cancer
393 associated with DM in East Asia is nasopharyngeal carcinoma, however, it is less
394 associated with immediate patient mortality. In contrast, ILD, particularly rapidly progressive
395 interstitial lung disease, is associated with high mortality rates within the first year of
396 diagnosis[74,75], thus, frequently necessitating aggressive immunosuppressive therapy in
397 ILD patients.[76–79] Further analysis of death causes, revealed a higher incidence of
398 deaths from infection in the non-pruritic group (NPG), within the first year of DM or PM
399 diagnosis. This supports the concept that non-pruritic patients may require higher doses of
400 steroids and immunosuppressants, to manage their disease.

401

402 The survival curve indicated a marked decline in survival during the first year in the NPG, a
403 pattern not observed in the pruritic group (PG). Previous studies illustrated that lung
404 complications are the major cause of death within the first 12 months, following DM and PM
405 diagnosis.[80,81] This disparity in survival between the PG and NPG was even more
406 pronounced among DM patients. It is well-documented that DM is associated with a poorer
407 prognosis compared to PM, particularly concerning ILD[82] and cancer-related
408 mortality.[83,84] However, although no significant difference in ILD prevalence was
409 observed between the PG and NPG, the clinical course of ILD may vary considerably.
410 Rapidly progressive ILD is associated with significantly poorer prognosis, compared to

411 chronic ILD. This form of ILD is more prevalent in DM than in other connective tissue
412 diseases,[85] and has been extensively reported in Asia, including Japan, Hong Kong, and
413 Taiwan.[86–89]

414

415 Several hypotheses may explain the paradoxical finding of higher cancer risks but lower all-
416 cause mortality rates in our pruritic DM and PM patients. First, disease severity in the
417 nonpruritic group might be higher than in the pruritic group and required a higher dosage of
418 immunosuppressant. We observed that more patients in the nonpruritic group died from
419 infection, which was consistent with our hypothesis that nonpruritic patients require higher
420 dosages of immunosuppressants to control their disease. Secondly, the nonpruritic group
421 might consist of a higher prevalence of overlap syndrome. Researchers have categorized
422 DM into two groups: pure DM and overlap myositis with dermatomyositis features (OMDM).
423 [90] Pure DM is associated with higher cancer risks but an excellent 15-year survival rate of
424 92%. By contrast, patients with OMDM often develop myositis before cutaneous symptoms,
425 and possess a decreased 15-year survival rate of 65%. Thirdly, distinct myositis-specific
426 and myositis-associated autoantibodies might be involved in the pathogenesis of pruritic
427 and nonpruritic patients. Several autoantibodies may be candidates for pruritic and
428 nonpruritic conditions. Anti-transcriptional intermediary factor 1 γ (anti-TIF1 γ) antibodies
429 and anti-small ubiquitin-like modifier-1 activating enzyme (anti-SAE) antibodies are often
430 associated with extensive skin involvement and a higher risk of cancer.[91–95] Conversely,
431 patients with anti-melanoma differentiation-associated protein 5 (anti-MDA5) antibodies and
432 anti-signal recognition particle (anti-SRP) antibodies typically present with less pruritic skin
433 lesions, and a poor prognosis, despite having a lower risk of cancer.[91,96,97]Further
434 investigation is warranted to prove our hypotheses.

435

436 This study has several limitations. First, because our analysis relied on data from an
437 administrative database, some potential ascertainment problems were unavoidable,
438 including coding errors and mortality misclassifications. However, differences in coding
439 error between the pruritic and non-pruritic groups are unlikely. Additionally, our study
440 benefited from the stringent regulation of Taiwan's Registry of Catastrophic Illness
441 Database, which requires DM or PM cases to meet the criteria set by Bohan and
442 Peter.[22,23] Secondly, although assessing pruritus through prescription medication is an
443 objective and quantitative approach, it inevitably underestimates patients with mild pruritus
444 who did not require a prescription, those who discontinued antipruritic medication due to
445 non-responsiveness, and those who used over-the-counter medications or traditional
446 Chinese herbal treatments for pruritus. Thirdly, we were unable to analyze clinical
447 parameters such as cutaneous manifestations other than pruritus, laboratory parameters,
448 and myositis-associated or specific antibodies because of the inherent limitations of the
449 NHIRD. Finally, given that the population data were derived from a single country (Taiwan),
450 particularly the significant association of dermatomyositis to nasopharyngeal cancer, further
451 research is required to assess the generalizability and reproducibility of these findings in
452 other populations.

453

454 **5 Conclusions**

455 This study employed nationwide insurance administration data, and revealed a
456 significant association between pruritus and cancer, as well as cancer-related mortality, in
457 patients with DM and PM. Thus, comprehensive cancer screening is recommended for
458 patients with DM or PM, particularly those presenting with pruritus. Notably, nonpruritic
459 patients were associated with a higher risk of all-cause mortality, especially during the first
460 year after diagnosis. Therefore, patients without pruritus may require vigilant management

461 for potentially life-threatening complications and comorbidities.

Reference

1. Bendewald MJ, Wetter DA, Li X, Davis MDP. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: A population-based study in Olmsted County, Minnesota. *Arch Dermatol*. 2010 Jan;146(1):26–30.
2. Kuo CF, See LC, Yu KH, Chou IJ, Chang HC, Chiou MJ, Luo SF. Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: A nationwide population study. *British Journal of Dermatology*. 2011 Dec;165(6):1273–9.
3. Ungprasert P, Cheungpasitporn W, Wijarnpreecha K, Ahuja W, Ratanasrimetha P, Thongprayoon C. Risk of ischemic stroke in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis. *Rheumatol Int*. 2015 May 1;35(5):905–9.
4. Zhen C, Wang Y, Wang H, Wang X. The risk of ischemic stroke in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis. *Clin Rheumatol*. 2021 Oct 1;40(10):4101–8.
5. Rai SK, Choi HK, Sayre EC, Antonio Aviña-Zubieta J. Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: A general population-based study. *Rheumatology (United Kingdom)*. 2016 Mar 1;55(3):461–9.
6. Lai YT, Dai YS, Yen MF, Chen LS, Chen HH, Cooper RG, Pan SL. Dermatomyositis is associated with an increased risk of cardiovascular and cerebrovascular events: A Taiwanese population-based longitudinal follow-up study. *British Journal of Dermatology*. 2013 May;168(5):1054–9.
7. Xiong A, Hu Z, Zhou S, Qiang Y, Song Z, Chen H, Xiang Q, Zhang Y, Cao Y, Cui H, Luo J, Wang Y, Yang Y, Cui B, Li M, Shuai S. Cardiovascular events in adult polymyositis and dermatomyositis: A meta-analysis of observational studies. Vol. 61, *Rheumatology (United Kingdom)*. Oxford University Press; 2022. p. 2728–39.

8. Yosipovitch G, Tan A, Losicco K, Manabat CG, Kannagra A, Carroll C, Chan YH, Ng P, Jorizzo J. A comparative study of clinical characteristics, work-up, treatment, and association to malignancy in dermatomyositis between two tertiary skin centers in the USA and Singapore. *Int J Dermatol*. 2013 Jul;52(7):813–9.
9. Kim HJ, Zeidi M, Bonciani D, Pena SM, Tiao J, Sahu S, Werth VP. Itch in dermatomyositis: the role of increased skin interleukin-31. *British Journal of Dermatology*. 2018 Sep 1;179(3):669–78.
10. Hundley JL, Carroll CL, Lang W, Snively B, Yosipovitch G, Feldman SR, Jorizzo JL. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. *J Am Acad Dermatol*. 2006 Feb;54(2):217–20.
11. Shirani Z, Kucenic MJ, Carroll CL, Fleischer AB, Feldman SR, Yosipovitch G, Jorizzo JL. Pruritus in adult dermatomyositis. *Clin Exp Dermatol*. 2004 May;29(3):273–6.
12. Goreshi R, Chock M, Foering K, Feng R, Okawa J, Rose M, Fiorentino D, Werth V. Quality of life in dermatomyositis. *J Am Acad Dermatol*. 2011 Dec;65(6):1107–16.
13. Gobbi PG, Attardo-Parrinello G, Lattanzio G, Rizzo SC, Ascari E. Severe pruritus should be a B-symptom in Hodgkin's disease. *Cancer*. 1983;51(10):1934–6.
14. Feiner AS, Mahmood T, Wallner SF. Prognostic importance of pruritus in Hodgkin's disease. *JAMA*. 1978 Dec 15;240(25):2738–40.
15. Narita I, Alchi B, Omori K, Sato F, Ajiro J, Saga D, Kondo D, Skatsume M, Maruyama S, Kazama JJ, Akazawa K, Gejyo F. Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. *Kidney Int*. 2006 May;69(9):1626–32.
16. Gangat N, Strand JJ, Lasho TL, Li CY, Pardanani A, Tefferi A. Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis. *Am J Hematol*. 2008 Jun;83(6):451–3.

17. Johannesdottir SA, Farkas DK, Vinding GR, Pedersen L, Lamberg A, Sørensen HT, Olesen AB. Cancer incidence among patients with a hospital diagnosis of pruritus: A nationwide Danish cohort study. *British Journal of Dermatology*. 2014 Oct 1;171(4):839–46.
18. Su HJ, Chung WH, Lin CY. The associations between myositis autoantibodies and clinical presentations in dermatomyositis. *Australasian Journal of Dermatology*. 2022 Nov 1;63(4):479–87.
19. Gallais V, Crickx B, Belaich S. [Prognostic factors and predictive signs of malignancy in adult dermatomyositis]. *Ann Dermatol Venereol*. 1996;123(11):722–6.
20. Basset-Seguín N. Prognostic Factors and Predictive Signs of Malignancy in Adult Dermatomyositis. *Arch Dermatol*. 1990 May 1;126(5):633.
21. Lauinger J, Ghoreschi K, Volc S. Characteristics of dermatomyositis patients with and without associated malignancy. *JDDG - Journal of the German Society of Dermatology*. 2021 Nov 1;19(11):1601–11.
22. Bohan A, Peter JB. Polymyositis and Dermatomyositis. *New England Journal of Medicine*. 1975 Feb 20;292(8):403–7.
23. Bohan A, Peter JB. Polymyositis and Dermatomyositis. *New England Journal of Medicine*. 1975 Feb 13;292(7):344–7.
24. Chung WS, Lin CL, Sung FC, Lu CC, Kao CH. Increased Risk of Venous Thromboembolism in Patients with Dermatomyositis/Polymyositis: A Nationwide Cohort Study. *Thromb Res*. 2014 Sep;134(3):622–6.
25. Ting SW, Fan PC, Lin YS, Lin MS, Lee CC, Kuo G, Chang CH. Association between uremic pruritus and long-term outcomes in patients undergoing dialysis. *J Am Acad Dermatol*. 2020 Sep;83(3):924–5.
26. Kim HJ. Pruritus in autoimmune connective tissue diseases. *Ann Transl Med*. 2021

Mar;9(5):441–441.

27. Yahya A, Gideon P. S. Characterizing Pruritus in Autoimmune Connective Tissue Diseases. *J Drugs Dermatol*. 2019 Oct 1;18(10):995–8.
28. Razykov I, Levis B, Hudson M, Baron M, Thombs BD. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis: an updated analysis of 959 patients. *Rheumatology*. 2013 Nov;52(11):2056–61.
29. Razykov I, Thombs BD, Hudson M, Bassel M, Baron M, Canadian Scleroderma Research Group. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. *Arthritis Rheum*. 2009 Dec 15;61(12):1765–70.
30. Théréne C, Brenaut E, Sonbol H, Pasquier E, Saraux A, Devauchelle V, Le Moigne E, Misery L, Abasq-Thomas C. Itch and systemic sclerosis: frequency, clinical characteristics and consequences. *Br J Dermatol*. 2017 May;176(5):1392–3.
31. Bernacchi E, Amato L, Parodi A, Cottoni F, Rubegni P, De Pità O, Papini M, Rebora A, Bombardieri S, Fabbri P. Sjögren's syndrome: a retrospective review of the cutaneous features of 93 patients by the Italian Group of Immunodermatology. *Clin Exp Rheumatol*. 2004;22(1):55–62.
32. Valdes-Rodriguez R, Rowe B, Lee H, Moldovan T, Chan Y, Blum M, Yosipovitch G. Chronic Pruritus in Primary Sjögren's Syndrome: Characteristics and Effect on Quality of Life. *Acta Dermato Venereologica*. 2017;97(3):385–6.
33. Samotij D, Szczęch J, Kushner CJ, Mowla MR, Dańczak-Pazdrowska A, Antiga E, Chasset F, Furukawa F, Hasegawa M, Hashizume H, Islam A, Ikeda T, Lesiak A, Polańska A, Misery L, Szepietowski JC, Tsuruta D, Adamski Z, Werth VP, Reich A. Prevalence of Pruritus in Cutaneous Lupus Erythematosus: Brief Report of a Multicenter, Multinational Cross-Sectional Study. *Biomed Res Int*. 2018;2018:3491798.

34. Yosipovitch G, Bernhard JD. Chronic Pruritus. *New England Journal of Medicine*. 2013 Apr 25;368(17):1625–34.
35. Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. *Nat Rev Drug Discov*. 2008 Jan;7(1):41–53.
36. Vasiadi M, Kalogeromitros D, Kempuraj D, Clemons A, Zhang B, Chliva C, Makris M, Wolfberg A, House M, Theoharides TC. Rupatadine Inhibits Proinflammatory Mediator Secretion from Human Mast Cells Triggered by Different Stimuli. *Int Arch Allergy Immunol*. 2010;151(1):38–45.
37. Weller K, Maurer M. Desloratadine Inhibits Human Skin Mast Cell Activation and Histamine Release. *Journal of Investigative Dermatology*. 2009 Nov;129(11):2723–6.
38. Song J, Xian D, Yang L, Xiong X, Lai R, Zhong J. Pruritus: Progress toward Pathogenesis and Treatment. *Biomed Res Int*. 2018;2018:1–12.
39. Greaves MW. Pathogenesis and Treatment of Pruritus. *Curr Allergy Asthma Rep*. 2010 Jul 29;10(4):236–42.
40. Ring J, Hein R, Gauger A, Bronsky E, Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. *Int J Dermatol*. 2001 Jan 21;40(1):72–6.
41. Ortonne JP, Grob JJ, Auquier P, Dreyfus I. Efficacy and Safety of Desloratadine in Adults with Chronic Idiopathic Urticaria. *Am J Clin Dermatol*. 2007;8(1):37–42.
42. Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled trial*. *J Am Acad Dermatol*. 2003 Apr;48(4):535–41.

43. Grob J, Auquier P, Dreyfus I, Ortonne J. Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study. *Journal of the European Academy of Dermatology and Venereology*. 2008 Jan 20;22(1):87–93.
44. Yosipovitch G, Goon A, Wee J, Chan YH, Goh CL. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. *British Journal of Dermatology*. 2000 Nov 27;143(5):969–73.
45. Ständer S, Weisshaar E, Mettang T, Szepietowski J, Carstens E, Ikoma A, Bergasa N, Gieler U, Misery L, Wallengren J, Darsow U, Streit M, Metze D, Luger T, Greaves M, Schmelz M, Yosipovitch G, Bernhard J. Clinical Classification of Itch: a Position Paper of the International Forum for the Study of Itch. *Acta Derm Venereol*. 2007;87(4):291–4.
46. Theander E. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. *Ann Rheum Dis*. 2006 Jun 1;65(6):796–803.
47. Tzioufas AG, Voulgarelis M. Update on Sjögren's syndrome autoimmune epithelitis: from classification to increased neoplasias. *Best Pract Res Clin Rheumatol*. 2007 Dec;21(6):989–1010.
48. Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J, Hjalgrim H, Vineis P, Seniori Costantini A, Bracci PM, Holly EA, Willett E, Spinelli JJ, La Vecchia C, Zheng T, Becker N, De Sanjosé S, Chiu BCH, Dal Maso L, Cocco P, Maynadié M, Foretova L, Staines A, Brennan P, Davis S, Severson R, Cerhan JR, Breen EC, Birmann B, Grulich AE, Cozen W. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. *Blood*. 2008 Apr 15;111(8):4029–38.

49. Bernatsky S. Non-Hodgkin's lymphoma in systemic lupus erythematosus. *Ann Rheum Dis.* 2005 Oct 1;64(10):1507–9.
50. Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Petri M, Edworthy S, Barr S, Gordon C, Bae SC, Sibley J, Isenberg D, Rahman A, Aranow C, Dooley MA, Steinsson K, Nived O, Sturfelt G, Alarcón G, Senécal JL, Zummer M, Hanly J, Ensworth S, Pope J, El-Gabalawy H, McCarthy T, St. Pierre Y, Ramsey-Goldman R, Clarke A. An international cohort study of cancer in systemic lupus erythematosus. *Arthritis Rheum.* 2005 May 5;52(5):1481–90.
51. Bussone G, Mouthon L. Interstitial lung disease in systemic sclerosis. *Autoimmun Rev.* 2011 Mar;10(5):248–55.
52. Derk CT, Rasheed M, Artlett CM, Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. *J Rheumatol.* 2006 Jun;33(6):1113–6.
53. Pontifex EK, Hill CL, Roberts-Thomson P. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. *Ann Rheum Dis.* 2006 Sep 19;66(4):551–3.
54. Zhang W, Feng S, Yan S, Zhao Y, Li M, Sun J, Zhang FC, Cui Q, Dong Y. Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort. *Rheumatology.* 2010 Mar 1;49(3):571–7.
55. Weng MY, Huang YT, Liu MF, Lu TH. Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjögren's syndrome in Taiwan. *Ann Rheum Dis.* 2012 Apr;71(4):524–7.
56. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellekjaer L, Airio A, Evans SR, Felson DT. Frequency of specific cancer types in dermatomyositis and polymyositis: A population-based study. *Lancet.* 2001 Jan 13;357(9250):96–100.

57. Sigurgeirsson B, Lindelöf B, Edhag O, Allander E. Risk of Cancer in Patients with Dermatomyositis or Polymyositis. *New England Journal of Medicine* [Internet]. 1992 Feb 6;326(6):363–7. Available from: <http://www.nejm.org/doi/abs/10.1056/NEJM199202063260602>
58. Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: A Scottish population-based cohort study. *Br J Cancer*. 2001 Jul 6;85(1):41–5.
59. Motomura K, Yamashita H, Yamada S, Takahashi Y, Kaneko H. Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study. *Rheumatol Int*. 2019 Oct 1;39(10):1733–9.
60. Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang YT. Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. *Arthritis Res Ther*. 2010;12(2):R70.
61. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. *J Rheumatol*. 1994 Oct;21(10):1855–9.
62. Abu-Shakra M. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. *Ann Rheum Dis*. 2001 May 1;60(5):433–41.
63. András C, Csiki Z, Ponyi A, Illés Á, Dankó K. Paraneoplastic rheumatic syndromes. *Rheumatol Int*. 2006 Mar 10;26(5):376–82.
64. Maria José Leandro DAI. Rheumatic diseases and malignancy □? is there an association? *Scand J Rheumatol*. 2001 Jan 12;30(4):185–8.
65. Sigurgeirsson B, Lindelöf B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. *N Engl J Med*. 1992 Feb 6;326(6):363–7.
66. Dankó K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-term survival of

- patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. *Medicine*. 2004 Jan;83(1):35–42.
67. Bronner IM, van der Meulen MFG, de Visser M, Kalmijn S, van Venrooij WJ, Voskuyl AE, Dinant HJ, Linssen WHJP, Wokke JHJ, Hoogendijk JE. Long-term outcome in polymyositis and dermatomyositis. *Ann Rheum Dis*. 2006 Nov;65(11):1456–61.
 68. Santo AH, Souza JMP, Pinheiro CE, Souza DC, Sato EI. Trends in dermatomyositis- and polymyositis-related mortality in the state of São Paulo, Brazil, 1985-2007: multiple cause-of-death analysis. *BMC Public Health*. 2010 Oct 11;10:597.
 69. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, Komura K, Nakamura M, Koderia M, Suga N, Higashi A, Ogusu K, Tsutsui K, Furusaki A, Tanabe H, Sasaoka S, Muro Y, Yoshikawa M, Ishiguro N, Ayano M, Muroi E, Fujikawa K, Umeda Y, Kawase M, Mabuchi E, Asano Y, Sodemoto K, Seishima M, Yamada H, Sato S, Takehara K, Fujimoto M. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. *Arch Dermatol*. 2011 Apr;147(4):391–8.
 70. Limaye V, Hakendorf P, Woodman RJ, Blumbergs P, Roberts-Thomson P. Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis. *Intern Med J*. 2012 Feb;42(2):191–8.
 71. Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. *Curr Rheumatol Rep*. 2012 Jun;14(3):275–85.
 72. Schioppa E, Phillips K, MacDonald PM, Crofford LJ, Somers EC. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. *Arthritis Res Ther*. 2012 Jan 27;14(1):R22.
 73. Limaye V, Hakendorf P, Woodman RJ, Blumbergs P, Roberts-Thomson P. Mortality and its predominant causes in a large cohort of patients with biopsy-determined

- inflammatory myositis. *Intern Med J.* 2012 Feb;42(2):191–8.
74. So J, So H, Wong VTL, Ho R, Wu TY, Wong PCH, Tam LHP, Ho C, Lam TTO, Chung YK, Li WL, To CH, Lau CS, Mok CC, Tam LS. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis. *Rheumatology (Oxford).* 2022 Nov 2;61(11):4437–44.
75. Won Huh J, Soon Kim D, Keun Lee C, Yoo B, Bum Seo J, Kitaichi M, Colby T V. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. *Respir Med.* 2007 Aug;101(8):1761–9.
76. Suda T, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Naito T, Hashimoto D, Sato J, Toyoshima M, Hashizume H, Chida K. Interstitial lung diseases associated with amyopathic dermatomyositis. *Eur Respir J.* 2006 Nov;28(5):1005–12.
77. Kang EH, Lee EB, Shin KC, Im CH, Chung DH, Han SK, Song YW. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. *Rheumatology (Oxford).* 2005 Oct;44(10):1282–6.
78. Wang H, Lv J, He J, Wu W, Zhong Y, Cao S, Cai Y, Wang Q. The prevalence and effects of treatments of rapidly progressive interstitial lung disease of dermatomyositis/polymyositis adults: A systematic review and meta-analysis. *Autoimmun Rev.* 2023 Aug;22(8):103335.
79. Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. *Arthritis Rheum.* 2011 Nov;63(11):3439–47.
80. Dankó K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. *Medicine.* 2004 Jan;83(1):35–42.

81. Yamasaki Y, Yamada H, Ohkubo M, Yamasaki M, Azuma K, Ogawa H, Mizushima M, Ozaki S. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. *J Rheumatol*. 2011 Aug;38(8):1636–43.
82. Fujisawa T, Suda T, Nakamura Y, Enomoto N, Ide K, Toyoshima M, Uchiyama H, Tamura R, Ida M, Yagi T, Yasuda K, Genma H, Hayakawa H, Chida K, Nakamura H. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. *J Rheumatol*. 2005 Jan;32(1):58–64.
83. Airio A, Kautiainen H, Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. *Clin Rheumatol*. 2006 Mar;25(2):234–9.
84. Yamasaki Y, Yamada H, Ohkubo M, Yamasaki M, Azuma K, Ogawa H, Mizushima M, Ozaki S. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. *J Rheumatol*. 2011 Aug;38(8):1636–43.
85. Won Huh J, Soon Kim D, Keun Lee C, Yoo B, Bum Seo J, Kitaichi M, Colby T V. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. *Respir Med*. 2007 Aug;101(8):1761–9.
86. Lee CS, Chen TL, Tzen CY, Lin FJ, Peng MJ, Wu CL, Chen PJ. Idiopathic inflammatory myopathy with diffuse alveolar damage. *Clin Rheumatol*. 2002 Sep;21(5):391–6.
87. Kang EH, Lee EB, Shin KC, Im CH, Chung DH, Han SK, Song YW. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. *Rheumatology (Oxford)*. 2005 Oct;44(10):1282–6.
88. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, Komura K, Nakamura M, Koderia M, Suga N, Higashi A, Ogusu K, Tsutsui K, Furusaki A, Tanabe

- H, Sasaoka S, Muro Y, Yoshikawa M, Ishiguro N, Ayano M, Muroi E, Fujikawa K, Umeda Y, Kawase M, Mabuchi E, Asano Y, Sodemoto K, Seishima M, Yamada H, Sato S, Takehara K, Fujimoto M. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. *Arch Dermatol*. 2011 Apr;147(4):391–8.
89. Wang H, Lv J, He J, Wu W, Zhong Y, Cao S, Cai Y, Wang Q. The prevalence and effects of treatments of rapidly progressive interstitial lung disease of dermatomyositis/polymyositis adults: A systematic review and meta-analysis. *Autoimmun Rev*. 2023 Aug;22(8):103335.
90. Troyanov Y, Targoff IN, Payette MP, Raynauld JP, Chartier S, Goulet JR, Bourré-Tessier J, Rich E, Grodzicky T, Fritzler MJ, Joyal F, Koenig M, Sénécal JL. Redefining dermatomyositis: A description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features. *Medicine (United States)*. 2014 Nov 1;93(24):318–32.
91. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1- γ antibodies have clinical significance for patients with dermatomyositis. *Rheumatology*. 2010 Sep;49(9):1726–33.
92. Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1 γ antibodies in adults with dermatomyositis. *J Am Acad Dermatol*. 2015 Mar;72(3):449–55.
93. Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, Ishiguro N, Ueda-Hayakawa I, Asano Y, Ogawa F, Fujikawa K, Miyagi T, Mabuchi E, Hirose K, Akimoto N, Hatta N, Tsutsui K, Higashi A, Igarashi A, Seishima M, Hasegawa M,

- Takehara K. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. *Arthritis Rheum*. 2012 Feb 27;64(2):513–22.
94. Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, Rosen A, Casciola-Rosen L. Most Patients With Cancer-Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP-2 or Transcription Intermediary Factor 1 γ . *Arthritis Rheum*. 2013 Nov 28;65(11):2954–62.
95. Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WER, Cooper RG, McHugh NJ. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. *Ann Rheum Dis*. 2009 Oct 1;68(10):1621–5.
96. DeWane ME, Waldman R, Lu J. Dermatomyositis: Clinical features and pathogenesis. *J Am Acad Dermatol*. 2020 Feb;82(2):267–81.
97. Watanabe Y, Uruha A, Suzuki S, Nakahara J, Hamanaka K, Takayama K, Suzuki N, Nishino I. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. *J Neurol Neurosurg Psychiatry*. 2016 Oct;87(10):1038–44.

Figure Captions

Fig 1 Study design. Patients with dermatomyositis and polymyositis were extracted from National Health Insurance Research Database in Taiwan from 2005 to 2022.

Fig 2 Survival curves. Upper, overall cohort (dermatomyositis and polymyositis); middle, dermatomyositis; lower, polymyositis.

Tables

Table 1. Distributions of baseline characteristics in dermatomyositis and polymyositis cohort, by pruritus status, in 2005–2022.

	Overall cohort				Dermatomyositis				Polymyositis			
	LPG N=461	SPG N=458	NPG N=919	p	LPG N=288	SPG N=242	NPG N=427	p	LPG N=173	SPG N=216	NPG N=492	p
Male, n (%)	164 (35.57)	160 (34.93)	324 (35.26)	-	104 (36.11)	86 (35.54)	147 (34.43)	-	60 (34.68)	74 (34.26)	177 (35.98)	-
Age at index date, year, n (%)												
mean (SD)	52.0 (14.15)	51.6 (14.91)	51.8 (14.62)	0.94	52.2 (10.01)	50.9 (14.82)	52.1 (14.40)	0.32	51.7 (14.40)	52.3 (15.01)	51.5 (14.83)	0.52
median (IQR)	53 (42-62)	53 (41-62)	52 (41-63)		53 (42-62)	51 (41-62)	51 (42-62)		53 (41-62)	54 (43-62)	53 (41-63)	
min, max	18, 88	18, 87	18, 89		18, 88	18, 86	18, 89		20, 84	19, 87	18, 87	
< 40	94 (20.39)	94 (20.52)	192 (20.89)	0.76	57 (19.79)	47 (19.42)	82 (19.20)	0.71	37 (21.39)	47 (21.76)	110 (22.36)	0.65
40-65	284 (61.61)	282 (61.57)	557 (60.61)		179 (62.15)	155 (64.05)	263 (61.59)		105 (60.69)	127 (58.80)	294 (59.76)	
> 65	83 (18.00)	82 (17.90)	170 (18.50)		52 (18.06)	40 (16.53)	82 (19.20)		31 (17.92)	42 (19.44)	88 (17.89)	
Co-morbidities, n (%)												
Diabetes mellitus	62 (13.45)	51 (11.14)	127 (13.82)	0.1	29 (13.54)	25 (10.33)	54 (12.65)	0.92	23 (13.29)	26 (12.04)	73 (14.84)	0.13
Hypertension	123 (26.68)	119 (25.98)	252 (27.42)	0.54	74 (25.69)	58 (23.97)	110 (25.76)	0.33	49 (28.32)	61 (28.24)	142 (28.86)	0.94
Vasculitis	5 (1.08)	3 (0.66)	3 (0.33)	0.07	NA	NA	NA	0.11	NA	NA	NA	0.32
Arthritis	22 (4.77)	23 (5.02)	43 (4.68)	0.66	13 (4.51)	9 (3.72)	26 (6.09)	0.38	9 (5.20)	14 (6.48)	17 (3.46)	0.09

IQR, interquartile range; SD, standard deviation.

Overall cohort: patients with dermatomyositis and polymyositis.

LPG, long-term pruritic group: receiving antipruritic agents for 84 consecutive days or more.

SPG, short-term pruritic group: receiving antipruritic agents for 42 consecutive days or more, but less than 84 days.

NPG, nonpruritic group: receiving antipruritic agents for less than 42 consecutive days.

Table 2. Distributions of cancer and all-cause mortality in dermatomyositis and polymyositis cohort, by pruritus status, in 2005–2022.

	LPG	SPG	NPG	p
Overall cohort	N=461	N=458	N=919	
Cancer#				
Overall period	92 (19.96)	67 (14.63)	95 (10.34)	0.0002
Ever registered in 5 years prior to index date	18 (3.90)	21 (4.59)	32 (3.48)	0.33
Ever registered in 10 years after index date	77 (16.70)	50 (10.92)	67 (7.29)	0.0002
Interstitial lung disease	151 (32.75)	125 (27.29)	283 (30.79)	0.39
All-cause mortality	140 (30.37)	136 (29.69)	347 (37.76)	<0.0001
Cancer-associated mortality	53 (11.50)	31 (6.77)	54 (5.88)	0.04
Dermatomyositis	N=288	N=242	N=427	
Cancer#				
Overall period	75 (26.04)	47 (19.42)	57 (13.35)	0.11
Ever registered in 5 years prior to index date	13 (4.51)	17 (7.02)	23 (5.39)	0.43
Ever registered in 10 years after index date	63 (21.88)	34 (14.05)	38 (8.90)	0.12
Interstitial lung disease	90 (31.25)	75 (30.99)	168 (39.34)	0.39
All-cause mortality	95 (32.99)	76 (31.40)	199 (46.60)	0.0007
Cancer-associated mortality	46 (15.97)	22 (9.09)	34 (7.96)	0.3
Polymyositis	N=173	N=216	N=492	
Cancer#				
Overall period	17 (9.83)	20 (9.26)	38 (7.72)	0.35
Ever registered in 5 years prior to index date	5 (2.89)	4 (1.85)	9 (1.83)	0.39
Ever registered in 10 years after index date	14 (8.09)	16 (7.41)	29 (5.89)	0.48
Interstitial lung disease	61 (35.26)	50 (23.15)	115 (23.37)	0.24
All-cause mortality	45 (26.01)	60 (27.78)	148 (30.08)	0.03
Cancer-associated mortality	7 (4.05)	9 (4.17)	20 (4.07)	1

Data are presented as *n* (%).

Overall cohort: patients with dermatomyositis and polymyositis.

LPG, long-term pruritic group: receiving antipruritic agents for 84 consecutive days or more.

SPG, short-term pruritic group: receiving antipruritic agents for 42 consecutive days or more, but less than 84 days.

NPG, nonpruritic group: receiving antipruritic agents for less than 42 consecutive days.

Patients had records available in the cancer registry between 5 years prior to and 10 years after the index date.

Table 3 Event risk in dermatomyositis cohort, 2005-2022.

	Adjusted hazard ratio (95% confidence interval)	
	Newly diagnosed cancer	All-cause mortality
Overall		
Pruritus (Yes vs. No)	1.492 (1.093-2.036)	0.489 (0.419-0.571)
Pruritus (vs. No)		
SPG	1.139 (0.775-1.674)	0.468 (0.385-0.568)
LPG	1.849 (1.314-2.602)	0.511 (0.424-0.617)
Dermatomyositis		
Pruritus (Yes vs. No)	1.707 (1.126-2.587)	0.413 (0.335-0.509)
Pruritus (vs. No)		
SPG	1.220 (0.733-2.029)	0.379 (0.291-0.495)
LPG	2.107 (1.360-3.266)	0.444 (0.349-0.564)
Polymyositis		
Pruritus (Yes vs. No)	0.874 (0.523-1.461)	0.515 (0.402-0.660)
Pruritus (vs. No)		
SPG	0.889 (0.482-1.639)	0.536 (0.396-0.726)
LPG	0.855 (0.443-1.652)	0.490 (0.355-0.675)

Data are presented as hazard ratio (95% confidence interval).

Overall cohort: patients with dermatomyositis and polymyositis.

LPG, long-term pruritic group: receiving antipruritic agents for 84 consecutive days or more.

SPG, short-term pruritic group: receiving antipruritic agents for 42 consecutive days or more, but less than 84 days.

NPG, nonpruritic group: receiving antipruritic agents for less than 42 consecutive days.

Post cancer model of patients without baseline cancer adjusted for sex, age, diabetes, hypertension, vasculitis(overall); sex, age, diabetes, hypertension (dermatomyositis); age, hypertension (polymyositis).

Post Interstitial lung disease model of patients without baseline cancer adjusted for sex, age, arthritis (overall, dermatomyositis); age (polymyositis).

All-cause death model adjusted for sex, age, diabetes, hypertension, arthritis, cancer, interstitial lung disease (overall); sex, age, diabetes, hypertension, cancer, interstitial lung disease (dermatomyositis, polymyositis).

Entire database

Covers more than 99% of Taiwan's 23 million residents

Index period

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.26.24314441>; this version posted September 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

January 2005

Patients with dermatomyositis and polymyositis
N=2723

December 2022

1. aged under 18-year-old, and unknown sex (N = 122)

2. other diseases associated with pruritus (N = 469)

Dermatomyositis, Polymyositis
N=2132

Categorize patients according to prescription history of anti-pruritic agents for 42 consecutive days or more

Study sample size

Pruritic group
N=1180

Non-pruritic group
N=952

Pruritic group
N=919

Matching by gender and date of birth (± 2 years) in a 1:1 ratio

Non-pruritic group
N=919

Antipruritic agents for 84 days or more


Antipruritic agents for 42 to 83 days

Long-term pruritic group
N=461


Short-term pruritic group
N=458

Non-pruritic group
N=919

Overall cohort



Dermatomyositis



Polymyositis

